Błąd cURL: Failed connect to www.viamedica.pl:443; Connection refused
Vol 71, No 2 (2020)
Clinical vignette
Published online: 2020-04-15

open access

Page views 2203
Article views/downloads 844
Get Citation

Connect on Social Media

Connect on Social Media

Difficulties in the diagnosis and treatment of malignant paraganglioma of the urinary bladder

Ewelina Rzepka1, Aleksandra Gilis-Januszewska1, Marta Opalińska12, Anna Sowa-Staszczak12, Alicja Hubalewska-Dydejczyk12
Pubmed: 32293698
Endokrynol Pol 2020;71(2):196-197.


Not required for Clinical Vignette.

Article available in PDF format

View PDF Download PDF file


  1. Zhai H, Ma X, Nie W, et al. Paraganglioma of the Urinary Bladder: A Series of 22 Cases in a Single Center. Clin Genitourin Cancer. 2017; 15(5): e765–e771.
  2. Asa SL, Ezzat S, Mete O. The Diagnosis and Clinical Significance of Paragangliomas in Unusual Locations. J Clin Med. 2018; 7(9).
  3. Janssen I, Chen CC, Millo CM, et al. PET/CT comparing (68)Ga-DOTATATE and other radiopharmaceuticals and in comparison with CT/MRI for the localization of sporadic metastatic pheochromocytoma and paraganglioma. Eur J Nucl Med Mol Imaging. 2016; 43(10): 1784–1791.
  4. Satapathy S, Mittal BR, Bhansali A. 'Peptide receptor radionuclide therapy in the management of advanced pheochromocytoma and paraganglioma: A systematic review and meta-analysis'. Clin Endocrinol (Oxf). 2019; 91(6): 718–727.
  5. Botling J, Lamarca A, Bajic D, et al. High-grade progression confers poor survival in pancreatic neuroendocrine tumors. Neuroendocrinology. 2019 [Epub ahead of print].
Błąd cURL: Failed connect to www.viamedica.pl:443; Connection refused